文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

多参数磁共振成像引导的剂量递增放疗治疗局限性前列腺癌:一项前瞻性2期试验

Multiparametric Magnetic Resonance Imaging- Guided Dose-Escalated Radiation Therapy for Localized Prostate Cancer: A Prospective Phase 2 Trial.
PubMed 文献 · Pract Radiat Oncol · 2023-11-02

这项2期试验纳入50例携带PI-RADS III-V病灶的局限性前列腺癌患者,采用图像引导的IMRT-SBRT联合方案对前列腺照射45 Gy/25次后追加18 Gy/3次,并对PI-RADS病灶同步整合加量21 Gy/3次。18个月时晚期≥3级泌尿生殖毒性和胃肠道毒性累积发生率分别为2%和0%。作者认为该方案毒性可接受,但需谨慎解读并需在更大样本中验证。

要点

  • 18个月时晚期1、2、3级泌尿生殖毒性累积发生率分别为18%、53%、2%。
  • 18个月时晚期1、2、3级胃肠道毒性累积发生率分别为31%、4%、0%。
  • 中位随访43.5个月,3例出现生化复发,均伴远处骨转移,3年无生化失败率为95.3%(95% CI,89.2%-100%)。

核心结论

  • 多参数MRI引导下对PI-RADS III-V病灶采用图像引导IMRT-SBRT联合方案进行剂量递增,与可接受的晚期胃肠道和泌尿生殖毒性风险相关。
  • 作者认为结果应谨慎解读,考虑到其单机构性质、样本量小和随访时间短,并应在更大规模的研究中验证。

研究设计与样本

  • 这是一项前瞻性2期试验,招募临床肿瘤分期为T1-T3bN0且至少有一个PI-RADS III-V病灶的局限性前列腺癌患者。
  • 总共50例患者入组,其中43例完成了至少18个月的随访。
  • 治疗方案为前列腺和精囊腺照射45 Gy/25次,随后前列腺追加18 Gy/3次,同时对PI-RADS病灶同步整合加量21 Gy/3次。
  • 主要终点为18个月时晚期≥3级泌尿生殖毒性和胃肠道毒性的累积发生率,采用美国国家癌症研究所不良事件通用术语标准4.0版。

主要发现

  • 18个月时晚期1级、2级、3级泌尿生殖毒性累积发生率分别为18%、53%、2%。
  • 1例患者出现3级血尿,需要膀胱镜引导下电灼止血。
  • 未观察到急性3级胃肠道或泌尿生殖毒性。
  • 18个月时晚期1级、2级、3级胃肠道毒性累积发生率分别为31%、4%、0%。
  • 中位随访43.5个月时,3例患者出现生化复发,均伴远处骨转移,无局部或淋巴结复发;3年无生化失败率为95.3%(95% CI,89.2%-100%)。

局限性

  • 原文指出结果应谨慎解读,考虑到其单机构性质、样本量小和随访时间短,并应在更大规模的研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This trial's purpose was to determine the late toxicity associated with dose escalation to Prostate Imaging Reporting and Data System (PI-RADS) III-V lesions on multiparametric magnetic resonance imaging (MRI) with an image guided combined IMRT-stereotactic body radiation therapy (SBRT) approach in men with localized prostate cancer. METHODS AND MATERIALS: In this phase 2 trial patients with localized prostate cancer with clinical tumor stage T1-T3bN0 and at least one PIRADS III-V lesion were recruited to receive 45 Gy in 25 fractions to the prostate and seminal vesicles followed by a boost of 18 Gy in 3 fractions to the prostate with a simultaneous integrated boost 21 Gy in 3 fractions to the PI-RADS lesion(s). The primary endpoint was the cumulative incidence of late grade ≥3 genitourinary and gastrointestinal toxicity by 18 months (National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0). RESULTS: Overall, 50 patients were enrolled in this study, and 43 patients completed at least 18 months of follow-up. The cumulative incidence of grade 1, 2, and 3 late genitourinary toxicity at 18 months was 18%, 53%, and 2%. One patient was noted to have grade 3 hematuria and needed cystoscopy-guided cauterization. No acute grade 3 gastrointestinal or genitourinary toxicities were observed. The cumulative incidence of grade 1, 2, and 3 late gastrointestinal toxicity at 18 months was 31%, 4%, and 0%, respectively. At a median follow-up of 43.5 months, 3 patients developed biochemical recurrence, each with distant bone metastases without local or nodal recurrence. At 3 years, freedom from biochemical failure rate was 95.3% (95% CI, 89.2%-100%). CONCLUSIONS: Multiparametric MRI-guided dose escalation to PI-RADS III-V lesions using a combined image guided IMRT-SBRT approach is associated with an acceptable risk of late gastrointestinal and genitourinary toxicity. The results should be interpreted with caution considering their single institutional nature, small sample size, and short follow-up and should be validated in a larger study.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Camden N, Blumenfeld P, Roy S, et al. Multiparametric Magnetic Resonance Imaging- Guided Dose-Escalated Radiation Therapy for Localized Prostate Cancer: A Prospective Phase 2 Trial. Pract Radiat Oncol. 2023. PMID: 37923137. doi:10.1016/j.prro.2023.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。